Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Optimising prophylaxis outcomes and costs in haemophilia patients switching to recombinant FVIII-Fc: a single-centre real-world experience.

1 Sept 2020

Abstract excerpt

BACKGROUND: The recombinant factor VIII (rFVIII)-IgG1 Fc fusion protein (rFVIII-Fc) was the first available extended half-life rFVIII, shown to prolong dosing intervals of individualised prophylaxis in patients with severe haemophilia A, maintaining low bleeding rates and unchanged or lower FVIII dose versus standard half-life (SHL) rFVIII. Few data are available about real-world experience with rFVIII-Fc,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Hemophilia Treatment and Research
Share to Platelet Disorders and Treatments
Share to Protein purification and stability

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31855153
DOI: 10.2450/2019.0220-19

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Optimising prophylaxis outcomes and costs in haemophilia patients switching to recombinant FVIII-Fc: a single-centre real-world experience.PMID 31855153Read ↗

Transition considerations for extended half‐life factor productsSemantic proximity Read ↗

Clinical evaluation of glycoPEGylated recombinant FVIII: Efficacy and safety in severe haemophilia ASemantic proximity Read ↗

On‐demand treatment of bleeds in haemophilia patients with inhibitors: strategies for securing and maintaining predictable efficacy with recombinant activated factor VIISemantic proximity Read ↗

Many factor VIII products available in the treatment of hemophilia A: an embarrassment of riches?Semantic proximity Read ↗

Long‐term safety and efficacy of recombinant factor VIII Fc fusion protein (rFVIIIFc) in subjects with haemophilia ASemantic proximity Read ↗

The importance of real-world data in evaluating the safety of biosimilars: a descriptive study of clinical practice in an oncohematological population.Semantic proximity Read ↗

Occurrence of FVIII Inhibitors in Hemophilia A Patients Following an Institutional Switch to a Third Generation B-Domain-Deleted FVIII.Semantic proximity Read ↗

The long and short of it: using the new factor products.Semantic proximity Read ↗

Variable pharmacokinetics of coagulation factor VIII in the perioperative setting complicates personalisation of treatment in patients with haemophilia ASemantic proximity Read ↗

Safety, efficacy and pharmacokinetics of rVIII-SingleChain in children with severe hemophilia A: results of a multicenter clinical trial.Semantic proximity Read ↗

Parameters influencing FVIII pharmacokinetics in patients with severe and moderate haemophilia A.Semantic proximity Read ↗

Efficacy, safety, and immunogenicity of rurioctocog alfa pegol for prophylactic treatment in previously treated patients with severe hemophilia A: a systematic review and meta-analysis of clinical trialsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.